Last Updated on October 9, 2024 by The Health Master
New Delhi: The U.S. Food and Drug Administration (USFDA) said it had approved Biogen Inc’s drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.
The drug, branded as Qalsody, got a green light under the agency’s accelerated approval pathway. Biogen will be required to provide more data on the drug’s effectiveness for it to remain on the market and for the USFDA to grant traditional approval.
Qalsody’s approval is based on data that showed it reduced levels of neurofilament protein, an indicator of nerve cell degeneration believed to be tied with progression of the symptoms of the disease.
The effect of the drug is “large enough that you can see that (the) disease is fundamentally different than it would have been if patients weren’t on the drug”, said Colin Quinn, a neurologist at Penn Medicine ahead of the approval.
Qalsody can be used to treat ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of the superoxide dismutase 1 (SOD1) protein, and is designed to suppress its production.
A panel of USFDA experts in March voted in favor of an accelerated approval, but the same panel voted that data from trials of the drug did not support full approval
To confirm the drug’s clinical benefit, Biogen is testing it in another late-stage study in patients who do not yet have symptoms.
Biogen said Qalsody will be priced within a range comparable to other recently launched ALS treatments. The company estimates out-of-pocket expense will be less than $50 per month for a majority of the patients, depending on their insurance plan.
Around 16,000 to 32,000 people have ALS in the U.S., of which 2 per cent cases are associated with SOD1 gene mutations, according to government data.
USFDA gives nod for Nitrofurantoin Oral Suspension USP
USFDA gives approval for Icosapent Ethyl Capsules
USFDA gives approval for Metoprolol Tartrate tablet
USFDA gives approval for Roflumilast Tablets 250 mcg
USFDA gives nod for Azithromycin, used in bacterial infections
Relabeling of drug prices based on recent price changes in NLEM products
Drug recall: Thyronorm tablets recalled due to this reason
Govt likely to announce National Medical Device Policy
UK MHRA gives marketing authorisation for Cisplatin
Drug alert: 48 out of 1497 samples declared as NSQ in March 2023
USFDA issues directive to Sun Pharma for corrective action: Mohali
Drug recall: Sun Pharma, Hetero recall these drugs
Medical Device alert: USFDA identifies recall of this Medical Device as most serious
Wet Granulation vs Dry Granulation: Understanding the Key Differences
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
